ContraFect Corp (OTCPK:CFRXQ)
$ 0.02235 0.00735 (49%) Market Cap: 239,000.00 Enterprise Value: -2.70 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

ContraFect Corp to Host Development Update Call Transcript

Oct 02, 2019 / 12:30PM GMT
Release Date Price: $295.2 (+2.50%)
Editor

Operator: Good morning and welcome to the ContraFect Corporation conference call. Currently, all participants are in listen-only mode. Please be advised that call is being recorded at the company's request.

I would now like to turn the call over to Mike Messinger, Chief Financial Officer. Please proceed.

Michael Messinger
ContraFect Corporation - CFO

Good morning everyone and welcome to ContraFect conference call to discuss our planned Phase 3 clinical trial for exebacase based on our successful end of Phase 2 meeting with the FDA.

With me today are Dr. Roger Pomerantz, ContraFect's Chief Executive Officer, Chairman and President; and Dr. Cara Cassino, our Chief Medical Officer and Executive Vice President of Research and Development. We will be hosting a question and answer session at the end of this call.

I also want to note a replay of this call will be available on our website. And we will post a new corporate presentation including all the new information regarding our Phase 3 plans on our website and filed in an 8-K later today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot